- Patrys (PAB) completes the first engineering run of its cancer antibody candidate, PAT-DX1, resulting in a lower drug product recoveries than expected
- The product yield from the fermentation process was consistent with the small scale pilot production run
- CEO and Managing Director James Campbell said while is happy with the yield, he is “clearly frustrated with the purification process”
- This has caused a six-month delay in the first human study of PAT-DX1, which is now planned for mid 2023
- On the market this morning, Patrys is down 21.6 per cent and trading at 2.9 cents per share
Patrys (PAB) has completed the first engineering run of its cancer antibody candidate, PAT-DX1, resulting in a lower drug product recoveries than expected.
The therapeutic antibody development company said the product yield from the fermentation process was consistent with the small scale pilot production run that was conducted previously.
“While we were very happy with the yield from the fermentation process in our first engineering run, we are clearly frustrated that the purification process did not perform as well as expected,” CEO and Managing Director James Campbell said.
Patrys is now currently working with its Contract Development Manufacturing Organisation to implement improvements for the large-scale purification process.
This has now caused a six-month delay in the first human study of PAT-DX1, which is now planned for mid-2023.
It is expected a further engineering run for PAT-DX1 using an improved large-scale purification process will commence in the second quarter of 2022.
“This set-back to the timing of our PAT-DX1 program is material, but is offset by the significant advances being made with the PATDX3 manufacturing program and a range of business development activities,” Mr Campbell said.
In other news, Nucleus Therapeutics, Partys’ wholly-owned subsidiary, has earned a $1,188,581 R&D Tax Incentive Refund for the 2020/2021 fiscal year.
On the market this morning, Patrys was down 21.6 per cent and is trading at 2.9 cents per share at 10:48 am AEDT.